<DOC>
	<DOCNO>NCT01392716</DOCNO>
	<brief_summary>This study evaluate efficacy safety MabThera/Rituxan ( rituximab ) treatment-naive patient non-bulky follicular non-Hodgkin ` lymphoma . The anticipated time study treatment 3 month .</brief_summary>
	<brief_title>A Study MabThera/Rituxan ( Rituximab ) Patients With Non-Bulky Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient 1875 year age Newly diagnose nonbulky follicular nonHodgkin 's lymphoma &gt; /=1 measurable lesion No prior treatment ( corticosteroid radiotherapy ) Transformed follicular lymphoma Cerebral meningeal lymphomaotus localization Uncontrolled concurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>